A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Pain
In brief
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses of VX-708 in healthy participants
Key facts
- Study ID
- NCT05518734
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 64
- Starts
- 2022-09-17
- Expected to finish
- 2023-03-07
- Last updated by the study team
- 2023-03-30
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion - Tempe — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.